PreludeDx Unveils AidaBreast™: A Groundbreaking Multi-Omic Test for Early-Stage Breast Cancer PreludeDx has announced the publication of its innovative AidaBreast™ test, a multi-omic approach to predict breast cancer recurrence and therapy benefits.

PreludeDx Unveils AidaBreast™: A Groundbreaking Multi-Omic Test for Early-Stage Breast Cancer #United_States #Breast_Cancer #PreludeDx #Laguna_Hills #AidaBreast

PreludeDx Unveils Groundbreaking Validation for AidaBreast™ Multi-Omic Test in Breast Cancer Recurrence Prediction PreludeDx introduces AidaBreast™, the first validated multi-omic test predicting locoregional recurrence risk and radiation therapy benefits, transforming breast cancer treatment.

PreludeDx Unveils Groundbreaking Validation for AidaBreast™ Multi-Omic Test in Breast Cancer Recurrence Prediction #USA #Breast_Cancer #PreludeDx #Laguna_Hills #AidaBreast